Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Abstract Background Afatinib has shown favorable response rates (RRs) and longer progression free survival (PFS) in lung cancer patients harboring EGFR mutations compared with standard platinum-based chemotherapy. However, serious adverse drug reactions (ADRs) limit the clinical application of afati...

Full description

Bibliographic Details
Main Authors: Yi-Chieh Chen, Ming-Ju Tsai, Mei-Hsuan Lee, Chia-Yu Kuo, Mei-Chiou Shen, Ying-Ming Tsai, Huang-Chi Chen, Jen-Yu Hung, Ming-Shyan Huang, Inn-Wen Chong, Chih-Jen Yang
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Cancer
Subjects:
Epidermal growth factor receptor tyrosine kinase inhibitor
Afatinib
Lower starting dose
Adverse drug reaction
Online Access:https://doi.org/10.1186/s12885-021-08235-3

Internet

https://doi.org/10.1186/s12885-021-08235-3

Similar Items